MX2009005679A - Fluoresceina sustancialmente pura. - Google Patents

Fluoresceina sustancialmente pura.

Info

Publication number
MX2009005679A
MX2009005679A MX2009005679A MX2009005679A MX2009005679A MX 2009005679 A MX2009005679 A MX 2009005679A MX 2009005679 A MX2009005679 A MX 2009005679A MX 2009005679 A MX2009005679 A MX 2009005679A MX 2009005679 A MX2009005679 A MX 2009005679A
Authority
MX
Mexico
Prior art keywords
substantially pure
pure fluorescein
fluorescein
directed
present
Prior art date
Application number
MX2009005679A
Other languages
English (en)
Inventor
Gregory Bydlinski
Gregg Robert Harris
Britt S Scott
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39327263&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009005679(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2009005679A publication Critical patent/MX2009005679A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82Xanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está dirigida a un proceso mejorado para producir fluoresceina sustancialmente pura, así como a composiciones de fluoresceina sustancialmente pura preparadas a través del proceso. La invención está dirigida de manera particular a la provisión de composiciones farmacéuticas para uso en angiografía. La fluoresceina sustancialmente pura producida por medio del proceso de la presente invención es de menor color, menor contenido de cloruro de sodio, y está sustancialmente libre de piridina.
MX2009005679A 2006-12-11 2007-12-04 Fluoresceina sustancialmente pura. MX2009005679A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86948806P 2006-12-11 2006-12-11
PCT/US2007/086390 WO2008073764A2 (en) 2006-12-11 2007-12-04 Substantially pure fluorescein

Publications (1)

Publication Number Publication Date
MX2009005679A true MX2009005679A (es) 2009-06-08

Family

ID=39327263

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005679A MX2009005679A (es) 2006-12-11 2007-12-04 Fluoresceina sustancialmente pura.

Country Status (16)

Country Link
US (1) US7982056B2 (es)
EP (2) EP2481741A1 (es)
JP (2) JP5384363B2 (es)
KR (2) KR101571409B1 (es)
CN (1) CN101605796B (es)
AR (1) AR064288A1 (es)
AU (1) AU2007333307B2 (es)
BR (1) BRPI0720088A2 (es)
CA (1) CA2671860C (es)
CL (1) CL2007003593A1 (es)
ES (1) ES2387925T3 (es)
MX (1) MX2009005679A (es)
RU (1) RU2477284C2 (es)
TW (1) TWI518089B (es)
WO (1) WO2008073764A2 (es)
ZA (1) ZA200903447B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101605796B (zh) * 2006-12-11 2012-10-03 爱尔康研究有限公司 基本上纯的荧光素
CN107660207B (zh) 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
JP2017095453A (ja) * 2015-11-12 2017-06-01 参天製薬株式会社 高純度フルオレセインナトリウム
US10293047B1 (en) 2017-11-15 2019-05-21 Paragon BioTeck, Inc. Fluorescein and benoxinate compositions
WO2020112901A1 (en) * 2018-11-29 2020-06-04 James Neena Singhal Ophthalmic solutions having visual marker for safer contact lens insertion and removal
CN113461651A (zh) * 2021-08-20 2021-10-01 山东绅联药业有限公司 一种高纯度荧光素的纯化方法
WO2023037158A1 (en) * 2021-09-09 2023-03-16 Macsen Drugs Process for preparation of crystalline fluorescein sodium from diacetylfluorescein or fluorescein
CN116023389A (zh) * 2021-10-25 2023-04-28 英格尔医药科技(上海)有限公司 荧光素钠的晶型a、其制备方法及其用途
EP4489796A1 (en) * 2022-03-07 2025-01-15 Opus Life Sciences, Llc Fluorescein formulations and kits
CN117285500B (zh) * 2022-06-17 2025-10-17 广西梧州制药(集团)股份有限公司 一种高纯度荧光素钠的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1965842A (en) 1931-11-21 1934-07-10 Nat Aniline & Chem Co Inc Production of hydroxybenzenephthaleins
DD136498A1 (de) 1978-05-11 1979-07-11 Friedmut Friedrich Verfahren zur herstellung von hochgereinigtem fluorescein fuer injektionszwecke
US5188934A (en) * 1989-11-14 1993-02-23 Applied Biosystems, Inc. 4,7-dichlorofluorescein dyes as molecular probes
US5637733A (en) * 1995-09-27 1997-06-10 Warner-Jenkinson Company, Inc. Syntheses of fluorescein compounds with excess resorcinol as a solvent
US6162931A (en) * 1996-04-12 2000-12-19 Molecular Probes, Inc. Fluorinated xanthene derivatives
DE19923168A1 (de) * 1999-05-20 2000-11-23 Roche Diagnostics Gmbh Neue Fluoreszenzfarbstoffe und ihre Verwendung als Fluoreszenzmarker
FR2846331B1 (fr) * 2002-10-29 2006-11-17 Synth Innove Lab Phtaleines de purete elevee et leur procede de preparation
RU2287007C1 (ru) * 2005-07-28 2006-11-10 Борис Маркович Болотин Бесцветные, растворимые в воде органические люминофоры
CN101605796B (zh) * 2006-12-11 2012-10-03 爱尔康研究有限公司 基本上纯的荧光素

Also Published As

Publication number Publication date
EP2114953B1 (en) 2012-06-06
ZA200903447B (en) 2010-08-25
RU2009126572A (ru) 2011-01-20
AU2007333307A1 (en) 2008-06-19
CL2007003593A1 (es) 2008-08-22
KR101571409B1 (ko) 2015-11-24
ES2387925T3 (es) 2012-10-04
HK1134288A1 (en) 2010-04-23
CA2671860A1 (en) 2008-06-19
KR20150013356A (ko) 2015-02-04
CN101605796B (zh) 2012-10-03
JP5384363B2 (ja) 2014-01-08
BRPI0720088A2 (pt) 2013-12-24
RU2477284C2 (ru) 2013-03-10
AR064288A1 (es) 2009-03-25
US20080176930A1 (en) 2008-07-24
CA2671860C (en) 2016-07-12
TWI518089B (zh) 2016-01-21
WO2008073764A2 (en) 2008-06-19
TW200838864A (en) 2008-10-01
EP2481741A1 (en) 2012-08-01
WO2008073764A3 (en) 2009-07-30
JP2013241472A (ja) 2013-12-05
KR20090086620A (ko) 2009-08-13
US7982056B2 (en) 2011-07-19
EP2114953A2 (en) 2009-11-11
CN101605796A (zh) 2009-12-16
AU2007333307B2 (en) 2013-05-23
JP2010512409A (ja) 2010-04-22

Similar Documents

Publication Publication Date Title
AR064288A1 (es) Fluoresceina sustancialmente pura
ECSP066373A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
BR112012004157B8 (pt) biomateriais, processo de misturar acp com hbc e uso dos mesmos
BRPI0924653B8 (pt) composto de ferro-oligossacarídeo, composição e uso de deste composto
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
TNSN07360A1 (en) Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
UY31870A (es) Receptor metabotrópico de glutamato potenciadores 286
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
BR112012013847A2 (pt) novos derivados de indolinona ciclopropano
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
NI201100011A (es) Derivados de piridino - piridinonas, su preparación y su aplicación en terapéutica.
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
UY32517A (es) Derivados de nicotinamida, su preparación y su aplicación en terapéutica
NI200900211A (es) Derivados de 7 - alquinil - 1, 8 - naftiridonas, su preparación y su aplicación en terapéutica.
UY32010A (es) Nuevas indolinonas, composiciones conteniéndolas y aplicaciones
CR20110209A (es) Composición farmacéutica sólida
BR112015002464B8 (pt) processo para a preparação de carbamat-benzoxazinona, carbamat-benzoxazinona e uso da carbamat-benzoxazinona
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
CR20120542A (es) HETEROARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS
CR10371A (es) Compuestos heterociclicos apropiados para tratar trastornos que responden a la moduilacion del receptor de serotonina 5ht6
NI201200104A (es) NUEVOS DERIVADOS DE (HETEROCICLO - PIPERIDINA CONDENSADA ) - ( PIPERAZINIL ) - 1 - ALCANONA O DE ( HETEROCICLO - PIRROLIDINA CONDENSADA ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
DOP2011000032A (es) Composicion farmaceutica solida
EA200701648A1 (ru) Замещённые пирролы и имидазолы, содержащие их композиции, способ получения и применение
ECSP10010642A (es) Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes

Legal Events

Date Code Title Description
FG Grant or registration